VRTX · Vertex Pharmaceuticals Incorporated
$438.712026-05-17Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$542
+23.5% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($420 · $705) Analysts Range ($441 · $607) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $7.6B | — | 47.5% | 14.2% | $3.1B | −$1.2B | $1.9B | 3.7% | — | 28.1% | $11.0B | $9.15 | — |
| 2022.Q4 | $8.9B | 17.9% | 62.4% | 21.5% | $4.4B | −$593MM | $3.8B | 5.5% | — | 40.8% | $10.5B | $12.97 | — |
| 2023.Q4 | $9.9B | 10.5% | 50.2% | 17.4% | $4.1B | −$1.3B | $2.8B | 5.4% | — | 32.1% | $15.1B | $14.13 | — |
| 2024.Q4 | $11.0B | 11.7% | -2.1% | 45.0% | −$128MM | −$2.0B | −$2.1B | 6.2% | — | -0.7% | $20.3B | $-2.09 | — |
| 2025.Q4 | $12.0B | 9.2% | 45.9% | 14.9% | $4.7B | −$2.8B | $1.9B | 5.9% | — | 21.1% | $24.2B | $15.44 | 20.3 |
| italics below = DCF projection · 10yr Rev CAGR: 8.6% |
| 2026.Q4 | $13.0B | +8.3% | 51.4% | 15.4% | $5.7B | −$2.0B | $3.7B | 6.0% | $3.5B | 22.5% | $26.2B | $17.11 | 25.6 |
| 2027.Q4 | $14.4B | +10.2% | 54.3% | 15.9% | $6.6B | −$2.6B | $4.0B | 6.3% | $3.5B | 23.9% | $28.8B | $19.81 | 22.1 |
| 2028.Q4 | $16.0B | +11.3% | 50.1% | 16.4% | $6.7B | −$3.1B | $3.6B | 6.5% | $3.0B | 22.1% | $31.9B | $20.21 | 21.7 |
| 2029.Q4 | $17.8B | +11.7% | 57.9% | 16.9% | $8.6B | −$3.5B | $5.1B | 6.8% | $3.9B | 25.5% | $35.4B | $25.89 | 16.9 |
| 2030.Q4 | $19.8B | +10.9% | 57.9% | 17.4% | $9.5B | −$3.6B | $5.8B | 7.0% | $4.3B | 25.4% | $39.0B | $28.54 | 15.4 |
|
| Term. Yr+ | $28.6B | 4.1% | 42.3% | 20.0% | $9.7B | −$2.1B | $7.6B | 8.6% | $84.5B | 19.0% | — | — | — |
Active scenario IV: $542 (+23.5% vs market)